Clinical Trial News and Research

RSS

CRI to honor three scientists for contributions to immunology and cancer immunotherapy research

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, will bestow its highest honors on three scientists who have made fundamental contributions to the fields of immunology and cancer immunotherapy.

10 Aug 2015

Mallinckrodt subsidiary to acquire Therakos for $1.325 billion

Mallinckrodt plc, a leading specialty biopharmaceutical company, and The Gores Group, a global investment firm, announced today that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt will acquire Therakos, Inc. a leading immunotherapy company in a transaction valued at approximately $1.325 billion.

10 Aug 2015

BioClinica announces launch of eHealth Cloud platform

BioClinica, Inc., a specialty clinical trials services and technology provider, today announced the launch of the BioClinica eHealth Cloud, a flexible and highly configurable platform offering that extends beyond the scope of traditional clinical trial technology approaches.

From Clario 10 Aug 2015

Flowonix Medical's new Patient Therapy Controller approved for market release

Flowonix Medical, Inc., announced today that its newest product, the Patient Therapy Controller (PTC), has been approved for market release. The PTC interfaces with the company's Prometra platform of intrathecal infusion devices. A small, hand-held device with a touch-screen, the PTC allows the patient to initiate a bolus delivery of medication from the implanted pump.

7 Aug 2015

Lexicon Pharmaceuticals' revenues decrease to $0.4 million in second quarter 2015

Lexicon Pharmaceuticals, Inc., today reported financial results for the second quarter ended June 30, 2015 and provided an overview of key milestones for the company's lead drug candidates.

7 Aug 2015

Experimental Ebola virus vaccine protects cynomolgus macaques against current EBOV outbreak strain

National Institutes of Health scientists report that a single dose of an experimental Ebola virus (EBOV) vaccine completely protects cynomolgus macaques against the current EBOV outbreak strain, EBOV-Makona, when given at least seven days before exposure, and partially protects them if given three days prior.

7 Aug 2015

Scientists develop biosensor to measure abnormal activity of cell 'fuel' carrier

To be able to function, cell mitochondria import "fuel" using a carrier, the Mitochondrial Pyruvate Carrier (MPC). In order to determine whether the MPC is still functional in malignant cells, the team of Professor Jean-Claude Martinou, at the University of Geneva, Switzerland, has just developed a biosensor to measure its live activity.

7 Aug 2015

Vtesse reports preliminary results from VTS-270 Phase 1 trial for treatment of Niemann-Pick Disease Type C

Vtesse, Inc. announced preliminary results today from an open-label Phase 1 clinical trial with VTS-270 (a formulation of (2-hydroxypropyl)-beta-cyclodextrin) for treatment of Niemann-Pick Disease Type C (NPC) conducted by researchers at the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development.

6 Aug 2015

Neovasc's second quarter revenues drop 18%

Neovasc Inc. today announced financial results for the quarter ended June 30, 2015.

6 Aug 2015

Pitt researchers figure out how to quantify beating action of cilia

Researchers at the University of Pittsburgh School of Medicine have figured out how to objectively quantify the beating action of cilia, the tiny, hair-like projections on cells that line nasal passages, the lungs and almost every other body tissue, according to a study published online today in Science Translational Medicine.

6 Aug 2015

Clinical study shows two-drug combination can prolong survival in men with metastatic prostate cancer

Newly diagnosed patients with metastatic, hormone-sensitive prostate cancer gained a dramatic survival benefit when started on two drugs simultaneously, rather than delaying the second drug until the cancer began to worsen, according to results of a clinical trial led by a Dana-Farber Cancer Institute scientist.

6 Aug 2015

AACN selects Linda L. Chlan as 2016 Distinguished Research Lecturer

The American Association of Critical-Care Nurses recently selected Linda L. Chlan, RN, PhD, FAAN, as its 2016 Distinguished Research Lecturer.

6 Aug 2015

Delcath Systems achieves record quarterly product revenue in Q2 2015

Delcath Systems, Inc., a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces financial results for the three and six months ended June 30, 2015.

5 Aug 2015

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced that it has committed more than $29.3 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development in the United States, Australia, Canada, France, Sweden, Switzerland, and The Netherlands.

5 Aug 2015

Resverlogix announces formation of international Clinical Steering Committee for RVX-208 "apabetalone" Phase 3 trial

Resverlogix Corp. is pleased to announce the formation of an international Clinical Steering Committee for the RVX-208 "apabetalone" Phase 3 clinical trial BETonMACE assessing major adverse cardiac events (MACE) in high-risk vascular patients with diabetes mellitus and a recent Acute Coronary Syndrome event. BETonMACE is expected to start in the fall of 2015.

4 Aug 2015

European Commission grants orphan drug designation to SGX301 for treatment of CTCL

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation to synthetic hypericin (the active pharmaceutical ingredient in SGX301) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare disease and a class of non-Hodgkin's lymphoma, a type of cancer of the white blood cells that are an integral part of the immune system.

4 Aug 2015

Syneron Medical's second quarter 2015 revenue up 14% to $73.5 million

Syneron Medical Ltd., a leading global aesthetic device company, today announced financial results for the three month period ended June 30, 2015.

4 Aug 2015

Ironshore partners with Restore Health to participate in HLD-200 clinical trial to treat ADHD

Ironshore Pharmaceuticals & Development, Inc. has signed an agreement with Restore Health, a company specializing in personalized medicine, to participate in the fulfillment of a double-blind clinical trial, designed to evaluate the safety and efficacy of HLD-200, a new drug in development to treat Attention-deficit/hyperactivity disorder (ADHD).

4 Aug 2015

Breakthroughs against Plasmodium falciparum pave way for latest advancement

When the highly-influential European Medicines Agency announced its recommendation to approve what could be the world's first licensed vaccine against malaria in infants and children, there was much celebrating in the research community at NYU Langone Medical Center.

4 Aug 2015

Research: Failure to control early, localized prostate cancer leads to poor clinical outcome

Failure to control early, localized prostate cancer results in a poor clinical outcome, according to research published in the International Journal of Radiation Oncology Biology Physics.

4 Aug 2015

Clinical Trial News and Research

CRI to honor three scientists for contributions to immunology and cancer immunotherapy research

Mallinckrodt subsidiary to acquire Therakos for $1.325 billion

BioClinica announces launch of eHealth Cloud platform

Flowonix Medical's new Patient Therapy Controller approved for market release

Lexicon Pharmaceuticals' revenues decrease to $0.4 million in second quarter 2015

Experimental Ebola virus vaccine protects cynomolgus macaques against current EBOV outbreak strain

Scientists develop biosensor to measure abnormal activity of cell 'fuel' carrier

Vtesse reports preliminary results from VTS-270 Phase 1 trial for treatment of Niemann-Pick Disease Type C

Neovasc's second quarter revenues drop 18%

Pitt researchers figure out how to quantify beating action of cilia

Clinical study shows two-drug combination can prolong survival in men with metastatic prostate cancer

AACN selects Linda L. Chlan as 2016 Distinguished Research Lecturer

Delcath Systems achieves record quarterly product revenue in Q2 2015

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

Resverlogix announces formation of international Clinical Steering Committee for RVX-208 "apabetalone" Phase 3 trial

European Commission grants orphan drug designation to SGX301 for treatment of CTCL

Syneron Medical's second quarter 2015 revenue up 14% to $73.5 million

Ironshore partners with Restore Health to participate in HLD-200 clinical trial to treat ADHD

Breakthroughs against Plasmodium falciparum pave way for latest advancement

Research: Failure to control early, localized prostate cancer leads to poor clinical outcome

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer